OncoZenge

6.47 SEK

-3.58 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-3.58 %

+27.11 %

+2.54 %

+17.42 %

+72.53 %

+42.35 %

+24.42 %

-

-47.13 %

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Market cap

81.83M SEK

Turnover

322.59K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.2

2026

Annual report '25

20.5

2026

Interim report Q1'26

27.5

2026

General meeting '26

All

Press releases

ShowingAll content types

Press releaseyesterday

OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge™ for Europe

Press release11/17/2025, 9:00 AM

OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge™

Press release10/31/2025, 9:41 AM

BioStock: OncoZenge gearing up for phase III after a strong quarter

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/30/2025, 1:52 PM

Redeye: OncoZenge (Q3 review) - Gearing up for a transformative 2026

Regulatory press release10/30/2025, 7:00 AM

OncoZenge AB Interim Report January 1 – September 30, 2025

Press release10/13/2025, 8:20 AM

BioStock: UCLA study provides OncoZenge with patient insights ahead of phase III

Press release10/9/2025, 6:45 AM

OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study

Regulatory press release10/8/2025, 5:50 PM

OncoZenge AB Nomination Committee Appointed

Press release9/22/2025, 1:20 PM

OncoZenge AB - Capital Markets Day 2025 On-Demand Video Now Available

Press release9/17/2025, 6:50 AM

OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™

Press release9/10/2025, 3:10 PM

OncoZenge AB appoints LINK Medical as CRO for BupiZenge™ Phase III execution

Press release8/27/2025, 2:00 PM

OncoZenge AB: Invitation to OncoZenge's Capital Markets Day on 18 September 2025

Press release8/21/2025, 9:46 AM

Redeye: OncoZenge Q2 - Financed for fully European phase III study

Regulatory press release8/21/2025, 6:00 AM

OncoZenge AB Interim Report January 1 - June 30, 2025

Press release8/13/2025, 9:35 AM

OncoZenge AB: OncoZenge Event Calendar September - December 2025

Press release8/13/2025, 8:55 AM

OncoZenge AB: OncoZenge Changes Reporting Language to English

Regulatory press release7/30/2025, 6:50 AM

OncoZenge AB: OncoZenge Provides Market and Strategy Update

Press release7/21/2025, 7:50 AM

OncoZenge AB: OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 Project

Regulatory press release7/17/2025, 6:45 AM

OncoZenge AB: OncoZenge and Molteni Farmaceutici Sign Amendment to Focus BupiZenge™ Phase 3 Project in Europe

Press release7/11/2025, 9:15 AM

OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.